Skip to content

CytoDyn Inc.: 10-Q filed 2020-04-09

What CytoDyn Inc. reported in its quarterly report filed 2020-04-09 (fiscal Q3 2020): 31 published measures, 83 facts as tagged in accession 0001193125-20-102675.

This filing

Form
10-Q (quarterly report)
Filed
2020-04-09
Fiscal period
fiscal Q3 2020
Accession
0001193125-20-102675 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CytoDyn Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-02-2938,817,936USD
At 2019-05-3120,874,125USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-02-2943,201,047USD
At 2019-05-3129,788,185USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-02-29-4,383,111USD
At 2019-11-30-13,631,597USD
At 2019-08-31-6,794,595USD
At 2019-05-31-8,914,060USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2020-02-297,057,366USD
At 2019-05-312,612,910USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2019-12-01 to 2020-02-29-35,767,729USD91
2019-06-01 to 2020-02-29-66,792,196USD274
2019-09-01 to 2019-11-30-14,860,468USD91
2019-06-01 to 2019-08-31-16,163,999USD92
2018-12-01 to 2019-02-28-12,573,811USD90
2018-06-01 to 2019-02-28-41,292,761USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2019-06-01 to 2020-02-29-39,492,199USD274
2018-06-01 to 2019-02-28-40,953,793USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2019-06-01 to 2020-02-2937,881USD274
2018-06-01 to 2019-02-283,182USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2019-06-01 to 2020-02-2943,120,937USD274
2018-06-01 to 2019-02-2841,319,159USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2019-06-01 to 2020-02-29-37,881USD274
2018-06-01 to 2019-02-28-3,182USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-02-29-296,683,031USD
At 2019-05-31-229,363,407USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2019-12-01 to 2020-02-290USD91
2019-06-01 to 2020-02-290USD274
2018-12-01 to 2019-02-280USD90
2018-06-01 to 2019-02-28-2,826,919USD273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2020-02-2957,517USD
At 2019-05-3129,251USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2019-06-01 to 2020-02-294,345,508USD274
2018-06-01 to 2019-02-282,891,548USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2019-12-01 to 2020-02-29-22,074,684USD91
2019-06-01 to 2020-02-29-46,827,733USD274
2018-12-01 to 2019-02-28-12,871,324USD90
2018-06-01 to 2019-02-28-42,047,810USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-02-2924,602,036USD
At 2019-05-315,369,420USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2019-12-01 to 2020-02-2911,262,624USD91
2019-06-01 to 2020-02-2918,364,066USD274
2018-12-01 to 2019-02-281,050,413USD90
2018-06-01 to 2019-02-282,955,386USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-02-2941,004,046USD
At 2019-05-3126,926,348USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2020-02-2934,179,451USD
At 2019-05-3116,239,434USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2020-02-2913,952,955USD
At 2019-05-3115,475,454USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2019-12-01 to 2020-02-2922,074,684USD91
2019-06-01 to 2020-02-2946,827,733USD274
2018-12-01 to 2019-02-2812,871,324USD90
2018-06-01 to 2019-02-2842,047,810USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2019-12-01 to 2020-02-2915,109,013USD91
2019-06-01 to 2020-02-2932,690,700USD274
2018-12-01 to 2019-02-289,022,223USD90
2018-06-01 to 2019-02-2833,294,771USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-02-29470,806,098shares
At 2019-05-31329,395,752shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2020-02-297,057,366USD
At 2019-05-313,466,509USD
At 2019-02-281,593,629USD
At 2018-05-311,231,445USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2020-02-29291,829,006USD
At 2019-05-31220,119,856USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2020-02-29205,428USD
At 2019-05-310USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2020-02-2913,952,955USD
At 2019-05-3115,475,454USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2019-12-01 to 2020-02-29-35,767,729USD91
2019-06-01 to 2020-02-29-66,792,196USD274
2018-12-01 to 2019-02-28-12,573,811USD90
2018-06-01 to 2019-02-28-44,119,680USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2019-12-01 to 2020-02-296,464,638USD91
2019-06-01 to 2020-02-2912,604,919USD274
2018-12-01 to 2019-02-283,345,179USD90
2018-06-01 to 2019-02-288,005,346USD273

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2019-06-01 to 2020-02-290USD274
2018-06-01 to 2019-02-28-2,826,919USD273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2019-06-01 to 2020-02-298,689USD274
2019-09-01 to 2019-11-30875,000USD91

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2019-06-01 to 2020-02-2915,895,589USD274

Inspect the source

Entity
CytoDyn Inc. / CIK 0001175680
Captured
2026-09-20T07:44:48.635Z
SEC response SHA-256
ccd180f98f5bd324896d13ce785229f8b7185dbfcf88932cc316c9c53bdaba90

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001175680.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))